Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome
作者： Shibo Jiang , Maria Elena Bottazzi , Lanying Du , Sara Lustigman , Chien-Te Kent Tseng
DOI: 10.1586/ERV.12.126
关键词: Binding domain 、 Immunology 、 Biology 、 Immune system 、 Recombinant DNA 、 Coronavirus 、 Antibody 、 Immunopathology 、 Antigen 、 Viral Vaccine 、 Virology
摘要: A subunit vaccine, RBD-S, is under development to prevent severe acute respiratory syndrome (SARS) caused by SARS coronavirus (SARS-CoV), which classified the US NIH as a category C pathogen. This vaccine comprised of recombinant receptor-binding domain (RBD) SARS-CoV spike (S) protein and formulated on alum, together with synthetic glucopyranosyl lipid A. The would induce neutralizing antibodies without causing Th2-type immunopathology. Vaccine being led nonprofit product partnership; Sabin Institute Texas Children’s Hospital Center for Development in collaboration two academic partners (the New York Blood University Medical Branch); an industrial partner (Immune Design Corporation); Walter Reed Army Research. roadmap RBD-S outlined goal manufacture clinical testing within next 5 years.
sci-hub.se 参考文章(42)
M. Daeron, F. Kien, I. Dutry, J. S.M. Peiris, R. Bruzzone, Martial Jaume, A. Roberts, Y. W. Kam, N. Escriou, B. Nal, K. Subbarao, P. H. Li, M. S. Yip, R. Altmeyer, C. Y. Cheung, SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement. Hong Kong Medical Journal. ,vol. 18, pp. 31- 36 ,(2012)
Yuxian He, Hong Lu, Pamela Siddiqui, Yusen Zhou, Shibo Jiang, Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Contains Multiple Conformation-Dependent Epitopes that Induce Highly Potent Neutralizing Antibodies The Journal of Immunology. ,vol. 174, pp. 4908- 4915 ,(2005) , 10.4049/JIMMUNOL.174.8.4908
Christopher B. Fox, Martin Friede, Steven G. Reed, Gregory C. Ireton, Synthetic and Natural TLR4 Agonists as Safe and Effective Vaccine Adjuvants Sub-cellular biochemistry. ,vol. 53, pp. 303- 321 ,(2010) , 10.1007/978-90-481-9078-2_14
Anjeanette Roberts, Damon Deming, Christopher D. Paddock, Aaron Cheng, Boyd Yount, Leatrice Vogel, Brian D. Herman, Tim Sheahan, Mark Heise, Gillian L. Genrich, Sherif R. Zaki, Ralph Baric, Kanta Subbarao, A Mouse-Adapted SARS-Coronavirus Causes Disease and Mortality in BALB/c Mice PLOS Pathogens. ,vol. 3, pp. 23- 37 ,(2007) , 10.1371/JOURNAL.PPAT.0030005
Wenhui Li, Michael J. Moore, Natalya Vasilieva, Jianhua Sui, Swee Kee Wong, Michael A. Berne, Mohan Somasundaran, John L. Sullivan, Katherine Luzuriaga, Thomas C. Greenough, Hyeryun Choe, Michael Farzan, Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. ,vol. 426, pp. 450- 454 ,(2003) , 10.1038/NATURE02145
Gaddam Narsa Goud, Vehid Deumic, Richi Gupta, Jill Brelsford, Bin Zhan, Portia Gillespie, Jordan L. Plieskatt, Eric I. Tsao, Peter J. Hotez, Maria Elena Bottazzi, Expression, purification, and molecular analysis of the Necator americanus glutathione S-transferase 1 (Na-GST-1): A production process developed for a lead candidate recombinant hookworm vaccine antigen Protein Expression and Purification. ,vol. 83, pp. 145- 151 ,(2012) , 10.1016/J.PEP.2012.03.013
Peter J. Hotez, Jeffrey M. Bethony, David J. Diemert, Mark Pearson, Alex Loukas, Developing vaccines to combat hookworm infection and intestinal schistosomiasis Nature Reviews Microbiology. ,vol. 8, pp. 814- 826 ,(2010) , 10.1038/NRMICRO2438
M. Bolles, D. Deming, K. Long, S. Agnihothram, A. Whitmore, M. Ferris, W. Funkhouser, L. Gralinski, A. Totura, M. Heise, R. S. Baric, A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge Journal of Virology. ,vol. 85, pp. 12201- 12215 ,(2011) , 10.1128/JVI.06048-11
Yuxian He, Qingyu Zhu, Shuwen Liu, Yusen Zhou, Baoan Yang, Jiaming Li, Shibo Jiang, Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines Virology. ,vol. 334, pp. 74- 82 ,(2005) , 10.1016/J.VIROL.2005.01.034
Susan L. Baldwin, Narek Shaverdian, Yasuyuki Goto, Malcolm S. Duthie, Vanitha S. Raman, Tara Evers, Farah Mompoint, Thomas S. Vedvick, Sylvie Bertholet, Rhea N. Coler, Steven G. Reed, Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine. ,vol. 27, pp. 5956- 5963 ,(2009) , 10.1016/J.VACCINE.2009.07.081